Literature DB >> 8082513

Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.

S Grimbert1, D Pessayre, C Degott, J P Benhamou.   

Abstract

The HMG-CoA reductase inhibitor, lovastatin, is known to induce asymptomatic liver dysfunction in a few patients. We report the case of an adult who suffered from clinical hepatitis three months after the onset of lovastatin administration. Manifestations included asthenia, jaundice, and increased aminotransferase and alkaline phosphatase activities. Histologic examination showed centrilobular necrosis, centrilobular cholestasis, and infiltrates with mononuclear and polymorphonuclear cells, including eosinophils. Withdrawal of lovastatin was followed by complete normalization of liver tests within two months.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8082513     DOI: 10.1007/bf02088142

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Lovastatin-induced hepatitis.

Authors:  D Raveh; R Arnon; A Israeli; S Eisenberg
Journal:  Isr J Med Sci       Date:  1992-02

2.  Lovastatin alone and in combination for treatment of primary hypercholesterolemia.

Authors:  E A Stein; G E Lamkin; D Z Bewley
Journal:  Prog Clin Biol Res       Date:  1988

Review 3.  HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.

Authors:  S M Grundy
Journal:  N Engl J Med       Date:  1988-07-07       Impact factor: 91.245

4.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia.

Authors:  H Mabuchi; T Haba; R Tatami; S Miyamoto; Y Sakai; T Wakasugi; A Watanabe; J Koizumi; R Takeda
Journal:  N Engl J Med       Date:  1981-08-27       Impact factor: 91.245

Review 5.  Extended clinical safety profile of lovastatin.

Authors:  G Mantell; M T Burke; J Staggers
Journal:  Am J Cardiol       Date:  1990-09-18       Impact factor: 2.778

6.  Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV.

Authors: 
Journal:  Arch Intern Med       Date:  1993-05-10

7.  Diltiazem and granulomatous hepatitis.

Authors:  N S Sarachek; R L London; T J Matulewicz
Journal:  Gastroenterology       Date:  1985-05       Impact factor: 22.682

8.  Acute cholestatic hepatitis during simvastatin administration.

Authors:  M Ballaré; M Campanini; E Catania; G Bordin; G Zaccala; A Monteverde
Journal:  Recenti Prog Med       Date:  1991-04

9.  Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys.

Authors:  T Komai; K Kawai; T Tokui; Y Tokui; C Kuroiwa; E Shigehara; M Tanaka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Apr-Jun       Impact factor: 2.441

10.  Cholestatic jaundice associated with lovastatin (Mevacor) therapy.

Authors:  M J McQueen
Journal:  CMAJ       Date:  1990-04-15       Impact factor: 8.262

  10 in total
  9 in total

Review 1.  How well tolerated are lipid-lowering drugs?

Authors:  B Tomlinson; P Chan; W Lan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

3.  In vitro study of lovastatin interactions with amiodarone and with carbon tetrachloride in isolated rat hepatocytes.

Authors:  A-Z Krasteva; M-K Mitcheva; M-S Kondeva-Burdina; V-A Descatoire
Journal:  World J Gastroenterol       Date:  2007-04-21       Impact factor: 5.742

Review 4.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

5.  Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy.

Authors:  C A Stein; Sanjay Goel; Reza Ghavamian
Journal:  Invest New Drugs       Date:  2007-01-11       Impact factor: 3.651

Review 6.  Drug-Induced Liver Injury: Pattern Recognition and Future Directions.

Authors:  Tanvir Haque; Eizaburo Sasatomi; Paul H Hayashi
Journal:  Gut Liver       Date:  2016-01       Impact factor: 4.519

7.  Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Rosanna Villani; Eliano Pio Navarese; Francesco Cavallone; Jacek Kubica; Francesco Bellanti; Antonio Facciorusso; Gianluigi Vendemiale; Gaetano Serviddio
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-05-05

8.  Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus.

Authors:  John Paul Pezacki; Selena M Sagan; Angela M Tonary; Yanouchka Rouleau; Sylvie Bélanger; Lubica Supekova; Andrew I Su
Journal:  BMC Chem Biol       Date:  2009-01-16

9.  Characterization of chemically induced liver injuries using gene co-expression modules.

Authors:  Gregory J Tawa; Mohamed Diwan M AbdulHameed; Xueping Yu; Kamal Kumar; Danielle L Ippolito; John A Lewis; Jonathan D Stallings; Anders Wallqvist
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.